SecBot SecBot
PRESS-RELEASE ·Filed Aug 16, 2026

MESO

Mesoblast Limited
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The completion of patient treatment in this pivotal Phase 3 trial is a major derisking milestone, but the binary outcome (top-line data) is not due until mid-CY2027. Traders should monitor for any interim data or regulatory updates. The RMAT designation and large addressable market support a bullish view, but the long timeline to data readout introduces uncertainty.

DirectionBullish
Confidencemedium
Horizonmonths

rexlemestrocel-L

▲ Bullish Named in this press release
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$17.02
T+0 close · Aug 16, 2026 · via day close
Latest settled
−17.80%
T+60 · $13.99
Vs SPY
−14.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $17.02entry
  2. T+1 · 3mo ago −2.06%α −1.38% · $16.67
  3. T+5 · 3mo ago −2.23%α −1.04% · $16.64
  4. T+20 · 2mo ago −13.40%α −11.42% · $14.74
  5. T+60 · 7d ago −17.80%α −14.86% · $13.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease, randomizing and treating 350 patients. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, enabling priority review upon BLA filing.

Key Facts

  • Completed patient treatment in pivotal Phase 3 trial MSB-DR004 for rexlemestrocel-L in chronic low back pain (CLBP) associated with degenerative disc disease.
  • 350 patients randomized and treated with either rexlemestrocel-L or sham injection.
  • Primary endpoint is durable pain reduction at 12 months; secondary endpoints include function, quality of life, and opioid cessation.
  • Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, allowing priority review upon BLA filing.
  • Top-line results expected in mid-CY2027 after last patient completes 12-month follow-up.
  • CLBP due to degenerative disc disease has a U.S. prevalence of over 7 million people.
  • Company claims potential peak year revenue of >US$10 billion with single-digit market penetration.

Financial Impact

Potential peak year revenue >US$10 billion claimed by company for single-digit market penetration in CLBP/DDD indication.

revenuepipeline value

Risk Factors

  • Top-line results may fail to meet primary endpoint, leading to significant downside.
  • Long timeline to data (mid-CY2027) means no near-term catalyst from this trial.
  • Company's peak revenue estimates are forward-looking and unvalidated.
  • Manufacturing or regulatory hurdles could delay BLA submission or approval.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345802

Track record

25 reports on MESO

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 16, 2026